Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
about
Essential thrombocythemiaThe diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markersTherapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesGenomic landscape of megakaryopoiesis and platelet function defectsRefractory anemia with ring sideroblasts and RARS with thrombocytosisRecent advances in the understanding of myelodysplastic syndromes with ring sideroblasts.SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD.NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignanciesA Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease.Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.Recent advances in the bcr-abl negative chronic myeloproliferative diseases.Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesMutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis.An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case reportLoss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasmsEpigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Update on genetic and molecular markers associated with myelodysplastic syndromes.Unraveling the molecular pathophysiology of myelodysplastic syndromes.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinasesMyelodysplastic syndromes: clinical practice guidelines in oncology.Prognostic molecular markers in myelodysplastic syndromes.Updates in cytogenetics and molecular markers in MDS.A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques.The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera.Detection of phospho-STAT5 in mast cells: a reliable phenotypic marker of systemic mast cell disease that reflects constitutive tyrosine kinase activation.Myeloproliferative neoplasms: Morphology and clinical practice.An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis.Identification of a novel erythroid-specific enhancer for the ALAS2 gene and its loss-of-function mutation which is associated with congenital sideroblastic anemia.
P2860
Q21202968-45B39CB8-342C-4DA0-89F6-F02E08187F60Q24675681-483B27AE-CE39-4411-9708-5073EE334C37Q26752940-8F4C0550-DE5F-4FA5-822B-8D4E7E9FE437Q26770869-B9DE2C15-138E-4D1F-A5E6-FBC88825000DQ28083238-75209447-8707-4BBC-87EB-44F41D789F74Q30249108-5D0D70A6-EE76-4AF7-82ED-419DC7E3582EQ33306707-E3DDDAB9-B27C-4315-92FE-671AAB0A6443Q33393647-80F1B61C-A14E-42C2-8A71-2A84E2DE7882Q33788643-02C93FAF-B77B-4823-A8D2-6117F5AED412Q34065882-E3BA5CA2-D464-45E1-87DE-0446E4798157Q34106883-69A6CDDE-250A-4939-A4F3-DBD19C50D35AQ34578265-1E4D67B9-D8B2-49C2-B3C1-FD8E612AA3FCQ34667249-A7D0D3A0-599E-4F3C-9211-49C27F283BB4Q34700606-D7FD2FAE-A6ED-49F1-AB44-0E6F95628858Q35126938-17F8F032-A3E0-408E-8F59-335FFBD703EAQ35132241-DF8D6F46-5F17-400B-9183-D6D438876B9CQ35346433-E62EE3E3-BE2F-4856-9F94-142C362E7999Q36094707-4D8E54E7-CB3C-4CE9-9E13-000142B7CD87Q36708989-13F122B6-3990-49C5-B1EB-99252B8ED185Q37204110-2F0FC7FD-55F8-4B62-B2CC-4A4431A6BB56Q37262428-97F5DFD2-19C2-4AD8-804B-30BE443A791DQ37310619-0454C17F-EB8B-4495-B0BD-D3302726A3E4Q37407161-DB456FFC-653E-499C-B86E-B5BE4A51FD7CQ37671806-394C26F7-5FF1-4A22-BC2E-20A9AAE8EFB9Q37687519-4C0CFE43-8FF9-47AA-B7D1-6EB471FB0D3FQ37723847-73691B98-1B25-4E09-9140-FE7C93E204B9Q37810120-6F0CC590-F0B6-4B2B-B4EB-C6581584DF0BQ37845723-B09BF4A4-51CA-4136-9C0C-563690927CE8Q37921836-A1B0C72E-05F2-47FD-A67D-86691AC2F011Q38014534-F9FB6917-E4CD-4985-8C8A-B7963DDFE2B0Q38061848-5B77CF35-E431-4CE2-877F-8CD2FF9BC56AQ38164139-4FAE5501-FD59-421F-A396-3484E0AAAF43Q38248429-7D1F8AF2-2B60-4171-941C-AEF6156ABEEAQ38403218-7497B222-D722-42B3-B4A0-66F2D3FB9891Q38431102-18CB5160-D0B0-40AD-AB4F-9FD13B3AA319Q38683559-64CF07BC-21A3-47E2-9702-863E4571F5DDQ39048645-D968DA34-FD4A-4E34-85E3-592BBEB091C9Q41490661-828131EB-48BF-4E1F-863A-0F32D2354CBBQ41684028-C033D1DF-294F-42C9-9780-8F4DF0A69ADEQ41813591-E1ACBA14-53C9-4DF3-97CC-15CD25A2B588
P2860
Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Refractory anemia with ringed ...... erized by JAK2 V617F mutation.
@en
Refractory anemia with ringed ...... erized by JAK2 V617F mutation.
@nl
type
label
Refractory anemia with ringed ...... erized by JAK2 V617F mutation.
@en
Refractory anemia with ringed ...... erized by JAK2 V617F mutation.
@nl
prefLabel
Refractory anemia with ringed ...... erized by JAK2 V617F mutation.
@en
Refractory anemia with ringed ...... erized by JAK2 V617F mutation.
@nl
P2093
P2860
P1433
P1476
Refractory anemia with ringed ...... erized by JAK2 V617F mutation.
@en
P2093
Eric D Hsi
Gurunathan Murugesan
Hadrian Szpurka
Jaroslaw P Maciejewski
Karl S Theil
Mikkael A Sekeres
Samer Aboudola
P2860
P304
P356
10.1182/BLOOD-2006-02-005751
P407
P577
2006-06-01T00:00:00Z